TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01739205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM-D Intervention
Description: Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
Study: NCT03088202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: E-learning lectures, group exercises, skills training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized care pathways
Description: Pathways for systematic follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care
Description: Compulsory referral to palliative care at inclusion
Study: NCT04064138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal block
Description: At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae plane block
Description: Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia
Study: NCT04494386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Lining Stem Cells (ULSC)
Description: IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Lining Stem Cells (ULSC)
Description: IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (carrier control)
Description: IV infusion of carrier control consisting of sterile saline for injection
Study: NCT00663416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx™-265: rhCG, then rEPO
Description: * rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Study: NCT01489696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral
Study: NCT00654888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALK (automated lamellar keratectomy)
Description: ALK is performed with a microkeratome, to make a free cap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: mitomycin 0,02%, 30 seconds after ALK
Study: NCT01933139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-visual presentation
Study: NCT03932435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisrt period TWLO_C
Description: First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisrt period TWLO
Description: First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout period
Description: 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout period
Description: 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second period TWLO_C
Description: Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second period TWLO
Description: Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Study: NCT00663416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Study: NCT02268916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: OT led counseling
Study: NCT03791398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 3 ONC201 375mg
Description: ONC201 375mg + Nivolumab 240mg IV flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 3 ONC201 375mg
Description: ONC201 375mg + Nivolumab 240mg IV flat dose
Study: NCT01089140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10mg/kg/hr
Description: Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg/h infusion
Description: Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline placebo
Study: NCT01823744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient supplementation
Study: NCT01910519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine plus AS03 adjuvant
Description: Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine without adjuvant
Description: Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart.
Study: NCT04307212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50% heart rate reserve (HRR) low intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50% heart rate reserve (HRR) low intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75% HRR moderate intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75% HRR moderate intensity exercise
Description: Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
Study: NCT02268916

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual education
Description: At the end of the study, will receive OT-led counseling
Study: NCT04628247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spring gravity bar
Description: 1. contain two wooden board length (160 cm) and width (15 cm)~2. contain pair of spring at every end of board~3. two wooden board connect in the middle
Study: NCT01607515

Intervention type: OTHER
Group type: OTHER
Intervention: Impedance cardiography
Description: noninvasive measure of cardiac index by impedance cardiography.
Study: NCT03585023

Intervention type: DIAGNOSTIC_TEST
Intervention: Spontaneous miscarriage
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
Study: NCT04307212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control no exercise
Description: Trained and untrained participants will have a no exercise control day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control no exercise
Description: Trained and untrained participants will have a no exercise control day
Study: NCT02422277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LI-ESWT group
Description: The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDE-5 inhibitors group
Description: The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
Study: NCT02755389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 L/min oxygen via conventional nasal cannulae
Description: Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 L/min oxygen via conventional nasal cannulae
Description: Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 L/min oxygen via high-flow nasal cannulae
Description: Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
Study: NCT02699281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultra-micronized palmitoylethanolamide
Description: ultra-micronized palmitoylethanolamide 600 mg twice a day
Study: NCT03585023

Intervention type: DIAGNOSTIC_TEST
Intervention: Spontaneous miscarriage
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Voluntary pregnancy interruption
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Voluntary pregnancy interruption
Description: Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
Study: NCT02699281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: um-PEA like placebo twice a day
Study: NCT00917046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: 3 weekly sessions of high-intensity interval training in 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate continuous training
Description: 3 weekly sessions of moderate continuous training for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation of regular moderate exercise
Description: Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
Study: NCT03586635

Intervention type: OTHER
Intervention: neurological exam
Description: Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application
Study: NCT03295968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise/Ibuprofen
Description: HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise/Ibuprofen
Description: HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise/Ibuprofen
Description: HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
Study: NCT04816500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic ischemic conditioning treatment instrument
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.

Intervention type: DRUG
Group type: OTHER
Intervention: Regular treatment
Description: Antiplatelet agents and statins administration, vascular risk factors control.
Study: NCT01280565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 7.5 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: IV bolus at 1,000 mg/m2 once every 3 weeks
Study: NCT00876811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
Study: NCT02937662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin at a dose of 10 mg/㎡/d on days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 100mg/㎡/d on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician-Directed Regimens without Cyclophosphamide
Description: Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
Study: NCT03039413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Cu-64-TP3805 Positron Emission Tomography scan
Study: NCT00323271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Description: CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional
Description: Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
Study: NCT01577966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA.
Study: NCT04078087

Intervention type: DRUG
Intervention: Non obese
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).

Intervention type: DRUG
Intervention: Obese.
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Study: NCT04715737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of vasopressin (20IU) intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo intranasally
Study: NCT01329705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized
Study: NCT02080065

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Study: NCT03674827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06936308
Description: PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06936308
Description: PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
Study: NCT02445222

Intervention type: GENETIC
Group type: OTHER
Intervention: Previously treated CAR-T patients
Description: Lentiviral-based CAR-T cell therapy